Illumina, Inc. (Nasdaq: Ilmn) introduced Promotetete, a revolutionary AI tool designed to detect the changes in the disease in non -coding genome promoting regions, areas often neglected in clinical diagnostics. Presented in Science, the study shows that Promote could explain up to 6% of cases of rare unheeded diseases, potentially doubling the success of the diagnosis when associated with existing AI tools.
A research establishment with health professionals surrounded by diagnostic equipment.
While most of the current diagnoses focus on regions coding for proteins, promotes analyzes promoting sequences, the main regulators of gene activity, using in -depth learning. “This opens up new possibilities for patients who had previously had no genetic response,” said Dr. Kyle Farh, head of the Illumina laboratory, Inc. (Nasdaq: Ilmn).
The tool joins the AI Illumina, Inc. portfolio (Nasdaq: ILMN), including Splicaia and Primateai-3D, and is integrated into its Dragen analysis system. It is available for free for academic research via Illumina connected software, offering pre -complete scores to quickly prioritize harmful mutations.
While we recognize the potential of ILMN to grow, our conviction lies in the conviction that certain AI actions are more promising to provide higher yields and have a limited risk of decline. If you are looking for a more promising stock of AI than MM and which has an upward potential of 100x, consult our report on this subject Stock ai the cheapest.
Read then: 10 best cancer actions in which invest in long -term gains And 10 The most occurred shares to buy according to the billionaires.
Disclosure: None.
